Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics is positioned for success in the cell therapy market with its unique KYV-101 and KYV-201 products targeting autoimmune diseases. The company has identified a sizable immediate addressable market and has already established partnerships with top academic centers. Its strong financials and potential for biologics-like margins further support a positive outlook, with upcoming catalysts in the form of a BLA submission and commercial build-out. Additionally, the promising data for its lead indication, SPS, and deepening response for gMG, highlight the potential for significant demand for its products.

Bears say

Kyverna Therapeutics is a small biopharmaceutical company with a limited pipeline and a focus on developing cell therapies for autoimmune diseases. While their recent Phase 1 data for their product candidate miv-cel in rheumatoid arthritis (RA) is positive, it only includes difficult-to-treat patients and does not fully justify the high valuation of the company. Additionally, there are risks involved in the development and approval of their product candidates, including potential lack of durable responses and long-term dilution risk, which could negatively impact the company's stock in the future.

KYTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 4 analysts, KYTX has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.